BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 9642119)

  • 21. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha.
    Zi X; Mukhtar H; Agarwal R
    Biochem Biophys Res Commun; 1997 Oct; 239(1):334-9. PubMed ID: 9345320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of cytotoxic effect of epidermal growth factor (EGF) on EGF receptor overexpressing cells is associated with attenuation of EGF receptor tyrosine kinase activity.
    Gardner DP; Shimizu N
    J Cell Physiol; 1994 Feb; 158(2):245-55. PubMed ID: 8106561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
    Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
    Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
    Tuck AB; Hota C; Wilson SM; Chambers AF
    Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J; Baselga J
    J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy.
    Ahmad N; Kalka K; Mukhtar H
    Oncogene; 2001 Apr; 20(18):2314-7. PubMed ID: 11402326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis.
    DiGiovanni J; Rho O; Xian W; Beltràn L
    Prog Clin Biol Res; 1994; 387():113-38. PubMed ID: 7972243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone attenuation of epidermal growth factor-induced mitogenesis.
    Wiepz GJ; Houtman JC; Cha D; Bertics PJ
    J Cell Physiol; 1997 Oct; 173(1):44-53. PubMed ID: 9326448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
    Zolfaghari A; Djakiew D
    Prostate; 1996 Apr; 28(4):232-8. PubMed ID: 8602399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.
    Han Y; Caday CG; Umezawa K; Nanda A
    Oncol Res; 1997; 9(11-12):581-7. PubMed ID: 9563005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.
    Kim S; Han J; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
    Anticancer Res; 2011 Nov; 31(11):3767-73. PubMed ID: 22110198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
    Coulson JM; Poyner DR; Chantry A; Irwin WJ; Akhtar S
    Mol Pharmacol; 1996 Aug; 50(2):314-25. PubMed ID: 8700139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.